Lessons from immuno-oncology: a new era for cancer nanomedicine?

Jiang, Wen; Hou, Yuan; Chan, Charles; Roemeling, Christina A. Von; Yan, Zuoqin; Kim, Betty Y.S.

doi:10.1038/nrd.2017.34

Cited by 37 publications

(25 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the stimulation of the immune system, which enables the recognition and attack of malignant cells, does not solely rely on tumor accumulation, but might as well be achieved or enhanced by targeting of immune cells, e.g., in liver, spleen, and lymph nodes. Thus, high affinity of many NPs to cells of the mononuclear phagocyte system as well as macrophage uptake might even be used to promote the desired immune-response ( Jiang et al, 2017a , b ).…”

Section: Combination Treatments With Plga Npsmentioning

confidence: 99%

PLGA-Based Nanoparticles in Cancer Treatment

et al. 2018

View full text Add to dashboard Cite

Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug delivery, hyperthermia, and photodynamic therapy. Poly (lactic-co-glycolic acid) (PLGA)-based materials are frequently used in such setups. This review article gives an overview of the properties of previously reported PLGA nanoparticles (NPs), their behavior in biological systems, and their use for cancer therapy. Strategies are emphasized to target PLGA NPs to the tumor site passively and actively. Furthermore, combination therapies are introduced that enhance the accumulation of NPs and, thereby, their therapeutic efficacy. In this context, the huge number of reports on PLGA NPs used as drug delivery systems in cancer treatment highlight the potential of PLGA NPs as drug carriers for cancer therapeutics and encourage further translational research.

show abstract

Section: Combination Treatments With Plga Npsmentioning

confidence: 99%

PLGA-Based Nanoparticles in Cancer Treatment

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Accordingly, strategies that reduce uptake by resident immune cells in the lung, liver, and spleen have been shown to prolong circulation times and improve delivery to the tumor [13–16]. More recently, it has been suggested that this uptake by immune cells could be exploited for immuno-oncology, and usher in a new era for cancer nanomedicine [17].…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery

Betker

Jones

Childs

et al. 2018

Journal of Controlled Release

View full text Add to dashboard Cite

Decades of research into improving drug delivery to tumors has documented uptake of particulate delivery systems by resident macrophages in the lung, liver, and spleen, and correlated short circulation times with reduced tumor accumulation. An implicit assumption in these studies is that nanoparticles present in the blood are available for distribution to the tumor. This study documents significant levels of lipoplex uptake by circulating leukocytes, and its effect on distribution to the tumor and other organs. In agreement with previous studies, PEGylation dramatically extends circulation times and enhances tumor delivery. However, our studies suggest that this relationship is not straightforward, and that particle sequestration by leukocytes can significantly alter biodistribution, especially with non-PEGylated nanoparticle formulations. We conclude that leukocyte uptake should be considered in biodistribution studies, and that delivery to these circulating cells may present opportunities for treating viral infections and leukemia.

show abstract

“…Some patients still suffer from metastasis and recurrence. OSCC is known to be an immunosuppressive cancer, and immunotherapy has been reported to no longer be effective [12], [13]. Therefore, the identification of more biomarkers and therapeutic targets is needed.…”

Section: Discussionmentioning

confidence: 99%

DZIP1 Promotes Proliferation, Migration, and Invasion of Oral Squamous Carcinoma Through the GLI1/3 Pathway

Yan

Deng

Zhang

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

BACKGROUND: DZIP1 is an oncogene involved in the progression and stemness of carcinoma through the Wnt/β-catenin pathway, and the potential mechanism of DZIP1 in oral squamous cancer remains unknown. The aim of this study was to uncover the effect and mechanism of DZIP1 in the progression of oral squamous carcinoma. METHODS: TCGA database scanning was applied to verify dysregulated genes in oral squamous carcinoma. quantitative real-time polymerase chain reaction, immunohistochemistry, and Western blotting assays were used to detect the expression of DZIP1 in tissues and cell lines. We established stable DZIP1-overexpressing and DZIP1 knockdown cell lines. We investigated the biological function and the underlying mechanism of DZIP1 through a series of experiments. RESULTS: DZIP1 was one of the genes discovered by the scanning strategy to be upregulated in cancer tissue and negatively correlated with the overall survival (OS) of patients. DZIP1 promotes proliferation, migration, and invasion in an oral squamous carcinoma cell line through EMT in a GLI1/3-dependent manner. CONCLUSIONS: DZIP1 promotes the proliferation, migration, and invasion of oral squamous carcinoma through the GLI1/3 pathway.

show abstract

Lessons from immuno-oncology: a new era for cancer nanomedicine?

Cited by 37 publications

References 6 publications

PLGA-Based Nanoparticles in Cancer Treatment

PLGA-Based Nanoparticles in Cancer Treatment

Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery

DZIP1 Promotes Proliferation, Migration, and Invasion of Oral Squamous Carcinoma Through the GLI1/3 Pathway

Contact Info

Product

Resources

About